Skip to content

Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations
Endometrial Carcinoma Fireside Chat *Pre-Test*

Before you view the activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.Where are you in your career?(Required.)
2.Diarrhea, nausea, and vomiting are common gastrointestinal toxicities associated with the use of pembrolizumab and lenvatinib combination therapy. Which other toxicity may occur if these gastrointestinal toxicities are not managed effectively?(Required.)
3.During treatment with pembrolizumab and lenvatinib, a patient develops grade 3 diarrhea. Lenvatinib is held and loperamide is prescribed, but grade 3 diarrhea persists. Which of the following would be an appropriate next step for this patient?(Required.)
4.A patient has been receiving a combination of pembrolizumab and lenvatinib for the past 12 months. At their most recent follow-up appointments they have presented with persistently high levels of thyroid stimulating hormone. Lenvatinib was withheld, but TSH levels remain high. Which drug might you suspect is the most likely underlying cause of this toxicity?(Required.)
5.During treatment with pembrolizumab and lenvatinib, a patient develops grade 3 hypertension. What is the most effective management strategy for this patient?(Required.)
6.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).(Required.)
Privacy & Cookie Notice